Longevity Peptides and Functional Reserve: An Evidence Audit of Approved Peptides Against the Capacities That Keep Older Adults Independent
Only five FDA-approved peptides have shown improvements in functional outcomes for older adults, with TB-500 lacking sufficient human data for efficacy claims.
Where it sits
this study against the rest of the tb-500 ac-lkktetq corpusSummary and findings
This paper evaluates FDA-approved peptides for their impact on functional reserve and resilience in aging, specifically in older adults. It identifies 26 peptides that may influence physiological capacities but notes that only five have shown improvements in loaded functional outcomes. TB-500 is mentioned as lacking adequate human data for claims of efficacy.
Abstract
Peptides are promoted as longevity and healthy-aging interventions, and US regulators are moving to widen access to unapproved ones. I asked which FDA-approved peptides have improved functional reserve and resilience in aging, measured as loaded function in older adults. Of 144 non-insulin peptide records from three published lists, 93 had current US prescribing information, and 26 of these could act on one of five physiological capacities that sustain reserve: bioenergetic capacity, endocrine signaling, proteostasis and mitochondrial quality control, hormetic stress response, and autonomic regulation. I searched PubMed for each. A peptide counted if a blinded controlled trial in older adults improved a loaded functional outcome such as walking capacity, strength or cognition. Five did, though only one has strong support. Semaglutide, tirzepatide and liraglutide improved walk distance; in two trials the gain rose with weight loss, and strength was not reported. Tesamorelin improved executive function in one trial of older adults. Teriparatide improved mobility after fracture but acts on bone, an actuator, rather than a regulatory capacity. None of the 26 moved a loaded outcome through proteostasis, hormesis or autonomic regulation, the targets claimed for unapproved longevity peptides such as BPC-157 and TB-500, which FDA found poorly characterized and without adequate human data. I set out the product-quality standards any peptide must meet before a clinical claim, and the endpoints that would make a claim about reserve falsifiable. Geroscience trials of peptides should require loaded functional endpoints and report reserve costs such as loss of lean mass and strength.
Background
This paper addresses the clinical question of which FDA-approved peptides can enhance functional reserve and resilience in aging populations. Prior research has suggested that peptides may serve as interventions for longevity and healthy aging, but evidence supporting their efficacy is limited. This study is significant as it systematically reviews the available data on peptides and their effects on older adults' functional capacities.
Methods
The study is a review of existing literature, analyzing 144 non-insulin peptide records from three published lists. Out of these, 93 had current US prescribing information, and 26 were assessed for their impact on five physiological capacities related to functional reserve. The primary outcome measures included loaded functional outcomes such as walking capacity, strength, and cognition in older adults.
Results
Five peptides were identified as having improved loaded functional outcomes in older adults. Semaglutide, tirzepatide, and liraglutide improved walking distance; however, strength improvements were not reported. Tesamorelin showed an improvement in executive function in one trial, while teriparatide improved mobility after fractures. Notably, none of the peptides addressed proteostasis, hormesis, or autonomic regulation.
Interpretation
Compared to prior literature, the findings indicate that while some peptides show promise in improving specific functional outcomes, the overall evidence remains weak, particularly for TB-500 and similar peptides. The effect sizes reported are not robust enough to warrant clinical recommendations, especially given the lack of data on critical endpoints. Limitations include reliance on existing studies with potential biases and the absence of new clinical trial data.
Key findings
- Five peptides improved loaded functional outcomes in older adults.
- Semaglutide, tirzepatide, and liraglutide improved walk distance; strength was not reported.
- Tesamorelin improved executive function in one trial of older adults.
- Teriparatide improved mobility after fracture but acts on bone, not regulatory capacity.
- None of the 26 peptides improved outcomes through proteostasis, hormesis, or autonomic regulation.
Limitations
- Relies on existing literature, no new clinical trial data.
- Limited evidence supporting most peptides.
- Small sample sizes in trials reviewed.
- Lack of strong support for claims regarding TB-500.